Business Context and Reporting Period
Company: Bond Laboratories, Inc. (Note: Metadata lists "FITLIFE BRANDS, INC." but the filing text identifies the issuer as Bond Laboratories, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: The Company develops and distributes healthy-living and nutritional products, primarily through two brands: "Fusion Premium Energy" (energy shots and related products) and "NDS Nutritional Products" (weight loss, sports nutrition, and general health supplements acquired in October 2008). The Company operates as a Small Business Issuer.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $2,507,893 | $226,717 |
| Cost of Goods Sold | $1,801,034 | $149,836 |
| Gross Profit | $706,859 | $76,881 |
| Gross Margin | 28.2% | 33.9% |
| Operating Expenses | $1,166,920 | $1,160,180 |
| Operating Loss | $(460,061) | $(1,083,299) |
| Net Loss | $(473,096) | $(1,076,779) |
| Cash and Equivalents (End of Period) | $244,196 | $8,094 |
| Total Assets | $5,516,384 | $5,361,707 |
| Total Liabilities | $2,412,411 | $2,293,296 |
| Stockholders' Equity | $3,103,973 | $3,068,411 |
Cash Flow Summary (Q1 2009):
- Net cash used in operating activities: $(378,925)
- Net cash used in investing activities: $0
- Net cash provided by financing activities: $359,742
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased approximately 1,000% (from $226,717 to $2.5 million) driven by the integration of NDS Nutritional Products and expanded distribution of Fusion energy products.
- Improved Loss Position: Net loss decreased significantly from $(1.08 million) in Q1 2008 to $(473,096) in Q1 2009, despite higher operating expenses, due to the substantial revenue growth.
- Expense Shifts: Selling and marketing expenses decreased by $124,369 compared to the prior year, attributed to reduced one-time launch costs (trade shows, athlete endorsements) in 2009. Conversely, depreciation and amortization increased to $68,515 from $9,172 due to the NDS acquisition assets.
- Liquidity Improvement: Cash on hand increased from $8,094 in March 2008 to $244,196 in March 2009, supported by equity financing.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the revenue growth to the successful integration of NDS and Fusion sales teams. They anticipate further synergies in military and sporting goods distribution. The Company consolidated corporate operations to Omaha, NE, expecting a decrease in administrative expenses as a percentage of revenue.
Recent Financing (Subsequent Events):
- April 20, 2009: Issued 78.3 Series B Preferred Shares for gross proceeds of $783,000.
- April 15, 2009: Secured a $250,000 line of credit with U.S. Bancorp, secured by inventory, with an interest rate of 3.5% plus one-month Libor (minimum 4.5%).
Risks and Contingencies:
- Capital Needs: The Company relies on additional private or public financing to pursue growth plans; failure to secure capital could materially adversely affect operations.
- Internal Controls: The Company lacks an independent audit committee and has limited segregation of duties due to its small size, though management deems controls effective.
- Market Risk: Common stock is subject to "penny stock" regulations and trades on the OTCBB, which may limit liquidity and increase volatility.
- Competition: The energy drink and nutritional supplement markets are highly competitive with established players (e.g., Red Bull, Monster).
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 1,000% revenue increase and the collectibility of the increased accounts receivable (which rose from $428k to $717k).
- Cash Burn Rate: Confirm the monthly cash requirement of approximately $125,000 against current cash reserves ($244k) and the status of the new $250k line of credit.
- Debt Obligations: Review the terms of the $1 million in total notes payable, including the affiliate note with Bershert LLC and secured promissory notes.
- Equity Dilution: Assess the impact of recent and subsequent equity issuances (Common and Preferred Series B) on existing shareholder value.
- Internal Controls: Evaluate the risks associated with the lack of an independent audit committee and segregation of duties in a small-cap issuer.